BioMarin rises after Q4 results beat estimates

BioMarin Pharmaceutical

20/02/2025 10:41

** Shares of drugmaker BioMarin Pharmaceutical  BMRN.O  rise
10.5% to $72.51 premarket
    ** Co, after market close on Wednesday, reported Q4 rev. of
$747 mln, beating estimate of $713.4 mln, as per data compiled
by LSEG
    ** Reported Q4 adj. profit of 92 cents per share vs estimate
of 53 cents per share
    ** Forecast 2025 adj. profit in the range of $4.20 to $4.40
per share, above estimate of $3.26 per share
    ** Brokerage Evercore ISI says BMRN's Q4 results are
"solid"; adds "it looks like investors may be willing to reward
the company for solid execution after all. This was indeed an
encouraging update on multiple fronts"
    ** Stock had fallen 31.8% in 2024

 (Reporting by Sneha S K)
 ((Sneha.SK@thomsonreuters.com;))